瑞舒伐他汀联合芪蛭通络胶囊治疗血脂水平正常急性脑梗死的疗效观察

Observation of Curative Effect of Rosuvastatin Combined with Qizhi Tongluo Capsule in Acute Cerebral Infarction Patients with Normal Cholesterol

目的:探讨瑞舒伐他汀联合芪蛭通络胶囊对血脂水平正常急性脑梗死患者超敏C反应蛋白(hs-CRP)的影响以及其临床疗效。方法:选取98例患者,随机分成对照组(49例)、治疗组(49例)。对照组:瑞舒伐他汀钙片10 mg.d-1口服;治疗组:加用芪蛭通络胶囊2.0 g,口服,2次/d。两组疗程均为14 d,基础治疗相同。结果:治疗后第8,15天的hs-CRP水平,均为治疗组比对照组明显降低(P<0.05);治疗后第8,15天的神经功能缺损评分,均为治疗组比对照组明显降低(P<0.01);治疗后第15天总有效率,治疗组比对照组明显增高(P<0.05)。结论:瑞舒伐他汀联合芪蛭通络胶囊对血脂水平正常急性脑梗死能促进神经功能恢复,疗效确切,优于瑞舒伐他汀单一用药。

Objective： To investigate the effect of rosuvastatin combined with Qizhi Tongluo capsule to high-sensitivity C-reactive protein （hs-CRP） in acute cerebral infarction patients with normal cholesterol, as well as its clinical efficacy. Method： Ninty-eight patients were selected and divided randomly into a control group （n = 49） and a treatment group （n = 49）. Patients in the control group were received 10 mg rosuvastatin calcium tablet treatment every day and others in the treatment group were added 0.2 g Qizhi Tongluo capsule 2 times a day based on foundation treatment. Result： hs-CRP levels and neural function defect scales of two groups on the 8th day and the 15th day after treatments were different. The differences were considered statistically significant, respectively, for P 〈 0.05 and P 〈 0.01. The total effective rates of two groups on the 15th day after treatments were respectively 81.6% and 95.9% （P 〈0.05）. Briefly, compared with the control group, hs-CRP levels and neural function defect scales in patients in the treatment group were lower, but the total effective rate was higher. Conclusion： Combination of rosuvastatin and Qizhi Tongluo capsule in acute cerebral infarction patients with normal cholesterol can promote neural function recovery, which is better than that of alone rosuvastatin.